HEALTH TECHNOLOGY VASOPRESSIN SAMBONG 250 MG TABLET VARENICLINE NICOTINE REPLACEMENT THERAPY 2.5% PERITONEAL DIALYSIS SOLUTION 0.1% SODIUM HYALURONATE (15 ML)
PROPONENT DOH Disease Prevention and Control Bureau Philippine Institute of Traditional and Alternative Health Care (PITAHC) DPCB - Lifestyle-Related Diseases Division DPCB - Lifestyle-Related Diseases Division Philippine General Hospital, National Kidney and Transplant Institute Asian Eyes Optical
TOPIC NOMINATION
APPRAISAL AND RECOMMENDATION
APPEALS ON PRELIMINARY HTAC RECOMMENDATION
FINAL RECOMMENDATION 28 February 2022 14 January 2022 17 May 2021 17 May 2021 17 February 2021 10 March 2021
DECISION OF THE SECRETARY OF HEALTH 02 March 2022 14 January 2022 17 May 2021 17 May 2021 19 February 2021 10 March 2021
DISSEMINATION Link to HTAC RecommendationLink to HTAC RecommendationLink to issuanceLink to issuanceLink to IssuanceLink to Issuance

HEALTH TECHNOLOGY ORAL PRE-EXPOSURE PROPHYLAXIS (PREP) TENOFOVIR/LAMIVUDINE/DOLUTEGRAVIR DOLUTEGRAVIR INACTIVATED POLIOVIRUS VACCINE (IPV) (TRANSITION FROM ONE- TO TWO-DOSE) 10- AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINES (PCV) (REASSESSMENT)
PROPONENT National AIDS and STI Prevention and Control Program - Philippines (NASPCP) National AIDS and STI Prevention and Control Program - Philippines (NASPCP) National AIDS and STI Prevention and Control Program - Philippines (NASPCP) DOH National Immunization Program DOH National Immunization Program
TOPIC NOMINATION
TOPIC PRIORITIZATION
SCOPING AND PROTOCOL DEVELOPMENT
ASSESSMENT
EVIDENCE APPRAISAL
PRELIMINARY RECOMMENDATION
APPEALS
RESOLUTION
FINAL RECOMMENDATION 17 December 2017 09 August 2021 21 September 2021 13 July 2021 14 August 2020
DECISION OF THE SECRETARY OF HEALTH 18 January 2022 01 September 2021 28 September 2021 10 September 2021 14 August 2020
DISSEMINATION Link to issuanceLink to Evidence SummaryLink to Evidence Summary and IssuanceLink to Evidence Summary and IssuanceLink to issuanceLink to Evidence SummaryLink to IssuanceLink to Evidence Summary
Name of Drug Status
Lapatinib in the treatment of HER2-positive breast cancer patients Published (23 June 2022)
Pazopanib as a second-line treatment for metastatic soft tissue sarcoma (mSTS) Published (12 July 2022)
Pertuzumab for HER2+ Breast Cancer Ongoing assessment
Sunitinib for Renal Cell Carcinoma Ongoing assessment
Pazopanib as treatment for Renal Cell Carcinoma Ongoing assessment
Eribulin for mSTS Ongoing assessment
Abiraterone for adult men with prostate cancer Ongoing assessment
Rituximab SC for Non-Hodgkin’s Lymphoma Ongoing assessment
Zoledronic acid for prevention of skeletal-related events in cancer patients Ongoing assessment
TACE with Mitomycin C for patients with non-resectable Hepatocellular Carcinoma Ongoing assessment
Nilotinib as first-line treatment for Chronic Phase-Chronic Myeloid Leukemia Ongoing assessment
Cerebrolysin for patients with acute ischemic stroke, dementia and traumatic brain injury Ongoing assessment
Insulin glargine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) Ongoing assessment
Insulin detemir (100 U/mL) Ongoing assessment
Insulin aspart (100 U/mL) Ongoing assessment
Insulin lispro (Mix - P 814 3ml pre-filled pen (100 U/mL); Insulin Lispro 100 Units/mL, 10 ml vial) Ongoing assessment
Insulin glulisine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) Ongoing assessment
Ticagrelor for the prevention of thrombotic events among patients with Acute Coronary Syndrome Ongoing assessment
Tirofiban HCl for treatment of unstable angina or non-Q wave myocardial infarction Ongoing assessment
Ivabradine for the treatment of stable angina pectoris among adult patients with coronary artery disease Ongoing assessment
Citicoline for acute and recovery phase of cerebral infarction (e.g., ischemia due to stroke) Ongoing assessment
Rivaroxaban for myocardial infarction with atrial fibrillation Ongoing assessment
Dabigatran for myocardial infarction with atrial fibrillation Ongoing assessment
Sitagliptin Ongoing assessment
Dapagliflozin Ongoing assessment
Aflibercept for wet age-related macular degeneration Ongoing assessment
Dexamethasone for diabetic macular edema Ongoing assessment
Ranibizumab for visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO) Ongoing assessment
Eltrombopag Ongoing assessment
PROCESS PEDIA VACCINATION 5 to 11 YRS OLD PEDIA VACCINATION 12 to 17 YRS OLD BOOSTER AND ADDITIONAL DOSE PFIZER ASTRAZENECA SINOVAC SPUTNIK V JOHNSON & JOHNSON MODERNA COVOVAX COVAXIN SINOPHARM
EUA Approval
Data Extraction and Synthesis
HTAC Recommendation
Decision of Secretary of Health
Dissemination Link to Evidence SummaryLink to Evidence SummaryLink to Evidence SummaryVersion 1Version 1Link to Evidence SummaryVersion 1Version 1Link to Evidence SummaryLink to Evidence SummaryLink to Evidence SummaryLink to Evidence Summary
Version 2Version 2Link to Evidence SummaryVersion 2Version 2
Version 3
HEALTH TECHNOLOGY CASIRIVIMAB+INDEVIMAB DEXAMETHASONE FAVIPIRAVIR REMDESIVIR BARICITINIB TOCILUZIMAB
PROPONENT Disease Prevention and Control Bureau (DPCB) Philippine Academy of Ophthalmology DOH Disease Prevention and Control Bureau DOH Disease Prevention and Control Bureau DOH Disease Prevention and Control Bureau DOH Disease Prevention and Control Bureau
TOPIC NOMINATION
TOPIC PRIORITIZATION
ASSESSMENT
RECOMMENDATION
DECISION OF THE SECRETARY OF HEALTH
DISSEMINATION Link to HTAC RecommendationLink to Signed Endorsement Letter and Evidence SummaryDexamethasoneLink to issuanceDexamethasoneLink to issuanceDexamethasoneLink to issuanceDexamethasoneLink to issuance
HEALTH TECHNOLOGY SELF ADMINISTERED ANTIGEN TEST KITS (SAAGT) RAPID ANTIGEN TEST KITS (APRIL 2021 UPDATE) RAPID ANTIGEN TEST KITS (SEPTEMBER 2021 UPDATE) RT-PCR TESTING (APRIL 2021 UPDATE)
PROPONENT National Task Force (NTF) PHST, (HTAC-initiated) PHST, (HTAC-initiated) SOH, (HTAC-initiated)
TOPIC NOMINATION
TOPIC PRIORITIZATION
ASSESSMENT
RECOMMENDATION 30 April 2020 27 September 2021 30 April 2021
DECISION OF THE SECRETARY OF HEALTH
DISSEMINATION Link to Signed Endorsement LetterLink to Evidence SummaryLink to Signed Endorsement LetterLink to Evidence SummaryLink to Signed Endorsement LetterLink to Evidence Summary